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Impaired fasting glucose (IFG) and im-paired glucose tolerance (IGT) repre-sent intermediate states between
normal fasting glucose (NFG) or normal
glucose tolerance (NGT), respectively,
and diabetes (1). The regulation of fasting
and glucose concentrations after an oral
glucose load is dependent on different
physiological mechanisms (2), and cur-
rent evidence suggests that IFG and IGT
have different pathophysiologies (3,4).
Measurement of fasting plasma glucose
(FPG) is the most frequently used screen-
ing test for diabetes. However, the oral
glucose tolerance test (OGTT) might be a
preferable test because FPG underesti-
mates the severity of glucose intolerance
(5,6) and because IFG and IGT define two
distinct populations with only partial
overlap (5,7,8). The present study was
undertaken to compare insulin sensitivity
and insulin secretion profiles associated
with different stages of hyperglycemia as
assessed by FPG only or by FPG and 2-h
plasma glucose during an OGTT.
RESEARCH DESIGN AND
METHODS— We analyzed data from
900 subjects without previously known di-
abetes who underwent an OGTT for diag-
nostic purposes at Fleury Institute, Sa˜o
Paulo, Brazil. A double-glycemic status was
determined for each subject. A first set was
based on FPG only as follows: NFG (FPG
5.6 mmol/l), IFG (5.6 mmol/l  FPG
7.0 mmol/l), and diabetes (FPG 7.0
mmol/l). Subjects with IFG were further
stratified into two groups according to the
severity of FPG: IFG new criteria (IFGnc)
(5.6 mmol/l FPG6.1 mmol/l) and IFG
old criteria (IFGoc) (6.1 mmol/l  FPG
7.0 mmol/l) (1). A second set of glycemic
status values was based on both FPG and
2-h plasma glucose as follows: NFG/NGT
(FPG5.6 mmol/l and 2-h plasma glucose
7.8 mmol/l), isolated IFG (5.6 mmol/l
FPG7.0 mmol/l and 2-h plasma glucose
7.8 mmol/l), isolated IGT (FPG 5.6
mmol/l and 7.8  2-h plasma glucose
11.1 mmol/l), combined IFG/IGT (5.6
mmol/l FPG7.0 mmol/l and 7.8 2-h
plasma glucose11.1 mmol/l), and diabe-
tes (FPG 7.0 mmol/l or 2-h plasma glu-
cose 11.1 mmol/l). -Cell function was
estimated as the ratio ofinsulin30–0 min to
glucose30 min (9). Insulin sensitivity was es-
timated by Matsuda’s composite index (10)
and by homeostasis model assessment of in-
sulin sensitivity (HOMA%S) (11). Differ-
ences between groups were assessed by
ANOVA with log-transformed data. Com-
parisons between pairs were made using the
Tukey-Kramer honestly significant differ-
ence (HSD) test. Insulin secretion was com-
pared between groups with adjustment for
insulin sensitivity levels (HOMA%S) during
regression analyses.
RESULTS— Subjects with IFGnc, IFGoc,
or diabetes as defined by FPG had lower
insulin sensitivity than subjects with
NFG, but there were no differences in in-
sulin sensitivity among the hyperglyce-
mic groups (Table 1). Insulin secretion
decreased with the severity of hyperglyce-
mia and was significantly different in all
intergroup comparisons.
When OGTT-based glycemic status
was considered, subjects with isolated IFG
or with isolated IGT had decreased insulin
sensitivity that was intermediate between
that of subjects with NFG/NGT and that of
subjects with both IFG/IGT and diabetes
(Table 1). The insulin30 – 0 min-to-
glucose30 min ratio was decreased in all
groups with hyperglycemia compared
with values in subjects with NFG/NGT.
Similar values were observed in subjects
with isolated IFG or with isolated IGT that
were intermediate between those in sub-
jects with NFG/NGT and those in subjects
with combined IFG/IGT or with diabetes.
We have looked at the correlation be-
tween hyperglycemic status determined
by FPG only and by FPG and 2-h plasma
glucose. FPG-based stratification under-
estimated the severity of hyperglycemia
and glucose intolerance, as 19% of sub-
jects with NFG had IGT and 3% had dia-
betes when we considered the OGTT-
based stratification. Moreover, 44% of
subjects with IFG in the FPG-based strat-
ification also had IGT and 24% had dia-
betes according to the OGTT-based
criteria.
CONCLUSIONS— We have observed
that the increase in the severity of hyper-
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glycemia assessed by FPG only or by the
OGTT is associated with different profiles
of insulin sensitivity and insulin secre-
tion. When glycemic status was assessed
by FPG only, differences in IFG and dia-
betes were best explained by the degree of
-cell defects, as both dysglycemic states
were associated with similar degrees of in-
sulin resistance. The new FPG cutoff for
defining IFG (5.6 mmol/l) identifies
subjects with decreased insulin sensitivity
and decreased -cell function compared
with subjects with NFG/NGT but with a
lesser degree of insulin secretion deficit
than subjects defined by the older FPG
cutoff (6.1 mmol/l). When we take into
account both FPG and 2-h plasma glu-
cose, the severity of hyperglycemia and
glucose intolerance was associated with
progressive decreases in insulin sensitiv-
ity and in insulin secretion.
These differences in insulin sensi-
tivity and insulin secretion profiles
when hyperglycemia was diagnosed by
FPG only or by the OGTT are due to the
underestimation by FPG of the severity
of glucose intolerance. Our results are
in agreement with other studies sug-
gesting that FPG remains a poor dis-
criminator of IGT and of diabetes (5,6).
Our analysis illustrates the effects of us-
ing FPG as the single test of glycemic
status. Even with the new cutoff for IFG
(FPG 5.6 mmol/l), 25% of subjects
with IGT or diabetes would be misclas-
sified as normal.
In summary, our data demonstrate
that different patterns of insulin sensi-
tivity and insulin secretion are associ-
ated with the increase in the severity of
hyperglycemia assessed by FPG only or
by FPG and the 2-h plasma glucose dur-
ing an OGTT.
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